Potential therapeutic approach of intravenous immunoglobulin against COVID-19

Since the outbreak of the novel coronavirus disease (COVID-19), the therapeutic and management options to reduce the burden of the COVID-19 disease are under investigation. IVIG therapy is used as an effective treatment for immunodeficient patients and patients with inflammatory or autoimmune condit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolahchi, Zahra, Sohrabi, Hanye, Ekrami Nasab, Sara, Jelodari Mamaghani, Hesan, Keyfari Alamdari, Maryam, Rezaei, Nima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501925/
https://www.ncbi.nlm.nih.gov/pubmed/34627384
http://dx.doi.org/10.1186/s13223-021-00609-3
_version_ 1784580774093127680
author Kolahchi, Zahra
Sohrabi, Hanye
Ekrami Nasab, Sara
Jelodari Mamaghani, Hesan
Keyfari Alamdari, Maryam
Rezaei, Nima
author_facet Kolahchi, Zahra
Sohrabi, Hanye
Ekrami Nasab, Sara
Jelodari Mamaghani, Hesan
Keyfari Alamdari, Maryam
Rezaei, Nima
author_sort Kolahchi, Zahra
collection PubMed
description Since the outbreak of the novel coronavirus disease (COVID-19), the therapeutic and management options to reduce the burden of the COVID-19 disease are under investigation. IVIG therapy is used as an effective treatment for immunodeficient patients and patients with inflammatory or autoimmune conditions. The therapeutic effect of IVIG in COVID-19 patients has been investigated. But, the results are controversial and some studies reported no benefit of IVIG therapy. More clinical trials on the effect of IVIG therapy in COVID-19 patients should be performed to establish a certain conclusion about IVIG effectiveness.
format Online
Article
Text
id pubmed-8501925
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85019252021-10-12 Potential therapeutic approach of intravenous immunoglobulin against COVID-19 Kolahchi, Zahra Sohrabi, Hanye Ekrami Nasab, Sara Jelodari Mamaghani, Hesan Keyfari Alamdari, Maryam Rezaei, Nima Allergy Asthma Clin Immunol Review Since the outbreak of the novel coronavirus disease (COVID-19), the therapeutic and management options to reduce the burden of the COVID-19 disease are under investigation. IVIG therapy is used as an effective treatment for immunodeficient patients and patients with inflammatory or autoimmune conditions. The therapeutic effect of IVIG in COVID-19 patients has been investigated. But, the results are controversial and some studies reported no benefit of IVIG therapy. More clinical trials on the effect of IVIG therapy in COVID-19 patients should be performed to establish a certain conclusion about IVIG effectiveness. BioMed Central 2021-10-09 /pmc/articles/PMC8501925/ /pubmed/34627384 http://dx.doi.org/10.1186/s13223-021-00609-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Kolahchi, Zahra
Sohrabi, Hanye
Ekrami Nasab, Sara
Jelodari Mamaghani, Hesan
Keyfari Alamdari, Maryam
Rezaei, Nima
Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title_full Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title_fullStr Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title_full_unstemmed Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title_short Potential therapeutic approach of intravenous immunoglobulin against COVID-19
title_sort potential therapeutic approach of intravenous immunoglobulin against covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501925/
https://www.ncbi.nlm.nih.gov/pubmed/34627384
http://dx.doi.org/10.1186/s13223-021-00609-3
work_keys_str_mv AT kolahchizahra potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19
AT sohrabihanye potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19
AT ekraminasabsara potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19
AT jelodarimamaghanihesan potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19
AT keyfarialamdarimaryam potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19
AT rezaeinima potentialtherapeuticapproachofintravenousimmunoglobulinagainstcovid19

Ejemplares similares